Pfizer Inc. (NYSE:PFE) Shares Sold by Oak Harbor Wealth Partners LLC

Oak Harbor Wealth Partners LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 65,792 shares of the biopharmaceutical company’s stock after selling 8,036 shares during the quarter. Oak Harbor Wealth Partners LLC’s holdings in Pfizer were worth $1,745,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the fourth quarter worth $28,000. Gladius Capital Management LP grew its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the period. Finally, Noble Wealth Management PBC acquired a new position in shares of Pfizer in the fourth quarter worth about $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $26.71 on Friday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a market capitalization of $151.35 billion, a PE ratio of 18.94, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business has a 50 day simple moving average of $26.30 and a 200-day simple moving average of $27.25.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the business earned $0.10 EPS. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, January 24th were issued a $0.43 dividend. The ex-dividend date of this dividend was Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.44%. Pfizer’s dividend payout ratio is currently 121.99%.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.06% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on PFE shares. Citigroup dropped their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Bank of America restated a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Wolfe Research began coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.